Somavert is a drug owned by Pharmacia And Upjohn Co. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 25, 2017. Details of Somavert's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5849535 | Human growth hormone variants |
Mar, 2017
(7 years ago) |
Expired
|
| US6057292 | Method for inhibiting growth hormone action |
Sep, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Somavert is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Somavert's family patents as well as insights into ongoing legal events on those patents.
Somavert's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Somavert's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 25, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Somavert Generics:
There are no approved generic versions for Somavert as of now.
About Somavert
Somavert is a drug owned by Pharmacia And Upjohn Co. It is used for treating acromegaly in patients who have not responded well to surgery, radiation therapy, or medical therapies. Somavert uses Pegvisomant as an active ingredient. Somavert was launched by Pharmacia And Upjohn in 2014.
Approval Date:
Somavert was approved by FDA for market use on 31 July, 2014.
Active Ingredient:
Somavert uses Pegvisomant as the active ingredient. Check out other Drugs and Companies using Pegvisomant ingredient
Treatment:
Somavert is used for treating acromegaly in patients who have not responded well to surgery, radiation therapy, or medical therapies.
Dosage:
Somavert is available in injectable form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 20MG/VIAL | INJECTABLE | Prescription | SUBCUTANEOUS |
| 10MG/VIAL | INJECTABLE | Prescription | SUBCUTANEOUS |
| 15MG/VIAL | INJECTABLE | Prescription | SUBCUTANEOUS |
Somavert is a drug owned by Pharmacia And Upjohn Co Llc. It is protected by 2 US drug patents filed in 2014 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 25, 2017. Details of Somavert's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US5849535 | Human growth hormone variants |
Mar, 2017
(7 years ago) |
Expired
|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6057292 | Method for inhibiting growth hormone action |
Sep, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Somavert is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Somavert's family patents as well as insights into ongoing legal events on those patents.
Somavert's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Somavert's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 25, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Somavert Generics:
There are no approved generic versions for Somavert as of now.
About Somavert
Somavert is a drug owned by Pharmacia And Upjohn Co Llc. It is used for treating acromegaly in patients who have not responded well to surgery, radiation therapy, or medical therapies. Somavert uses Pegvisomant as an active ingredient. Somavert was launched by Pharmacia in 2014.
Approval Date:
Somavert was approved by FDA for market use on 31 July, 2014.
Active Ingredient:
Somavert uses Pegvisomant as the active ingredient. Check out other Drugs and Companies using Pegvisomant ingredient
Treatment:
Somavert is used for treating acromegaly in patients who have not responded well to surgery, radiation therapy, or medical therapies.
Dosage:
Somavert is available in injectable form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 30MG/VIAL | INJECTABLE | Prescription | SUBCUTANEOUS |
| 25MG/VIAL | INJECTABLE | Prescription | SUBCUTANEOUS |